John Martin Docherty bought $4,989 of LEXX
President & CSO at Lexaria Bioscience Corp.. 5,376 shares at an average of $0.93, traded Jul 29, 2025, filed Jul 30, 2025.
Score components
- +20RolePresident
- 0Trade size$5k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context9% above the 52-week low; 75% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.8%, 3m +4.8%, 6m -16.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001348362-25-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 29, 2025 | POpen-market purchase common shares | +5,376 | $0.93 | $4,989 | 5,376 | Jul 30, 2025 |
Related signals
Other insiders at Lexaria Bioscience Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Lexaria Bioscience Corp. | Christopher Bunka Chief Executive Officer | $25k 27,500 shares | +11% | |
| 64Notable | Lexaria Bioscience Corp. | Richard Christopher Chief Executive Officer | $14k 15,000 shares | +30% | |
| 56Moderate | Lexaria Bioscience Corp. | Vanessa Carle Secretary | $683 750 shares | - | |
| 54Moderate | Lexaria Bioscience Corp. | William Edward McKechnie director | $4,532 5,000 shares | +38% | |
| 43Moderate | LEXXbuy Lexaria Bioscience Corp. | Richard Christopher Chief Executive Officer | $118k 50,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.